NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Parkinson's disease (PD) is characterized by progressive motor and non-motor symptoms, yet the longitudinal interplay between clinical progression and neurophysiological alterations remains underexplored. In this four-and-a-half-year longitudinal study, we assessed 22 individuals with PD using the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and transcranial magnetic stimulation (TMS) to evaluate cortical excitability. We analyzed changes in resting motor threshold (rMT) and cortical silent period (CSP) across disease stages and examined the impact of the COVID-19 pandemic on disease progression. We observed significant motor function and cortical excitability deterioration over time, with CSP exhibiting potential as a biomarker of disease progression. These alterations were more pronounced in advanced PD and during the post-pandemic period, underscoring the susceptibility of PD patients to environmental stressors. No significant sex-related differences were found in clinical or neurophysiological measures. Our findings highlight the potential of TMS in monitoring PD progression and suggest that integrating neurophysiological assessments into routine clinical practice may enhance patient management. Longitudinal neurophysiological biomarkers could provide insights into disease trajectory and inform therapeutic interventions.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.